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therapy with linezolid is that its prolonged use is associated with
myelosuppression, but given linezolid’s efficacy for treating serious
Gram-positive infections, activity against resistant pathogens and
equivalent intravenous-to-oral formulations, the benefits of linezolid
treatment may outweigh the potential risk of reversible myelo-
suppression. Neither alternative is mentioned in the article by
Bernard et al.1 We believe that any article that intends approaching
PTI therapy has to mention all the possible antimicrobial alternatives,
and clearly state that the mainstays of therapy are glycopeptides, at
least until well-designed trials show evidence of greater benefit of
other agents.
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Dear Sir,
We thank Parra-Ruiz et al.1 for their useful comments on alter-
native antimicrobial therapy for orthopaedic prosthetic infections
(OPIs) due to methicillin-resistant Staphylococcus aureus (MRSA)
or Staphylococcus epidermidis (MRSE). These infections are pro-
tracted and difficult to treat. In our article,2 we indicate that glyco-
peptides (vancomycin, teicoplanin) remain the primary drugs that
should be used for this indication.3 The combinations of fusidic acid
(or quinolone)4–rifampicin5 and trimethoprim–sulfamethoxazole6
for susceptible strains have been successfully used in OPI.
We clearly need more new drugs to treat MRSA infection. As
discussed by Parra-Ruiz et al.,1 both quinupristin–dalfopristin and
linezolid are interesting alternatives, but unfortunately, there is only
limited clinical experience with these compounds in osteomyelitis
or OPI. Peripheral vein toxicity with quinupristin–dalfopristin and
secondary effects upon prolonged therapy with linezolid7 are serious
concerns.
Daptomycin8 has recently been approved for the therapy of skin
and soft tissue infections. Novel glycopeptides such as dalbavancin9
and a novel cephalosporin active against MRSA activity10 are
promising drugs under development.
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